Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Glaukos Epioxa Keeps Keratoconus Gains at 3 Years
Glaukos Epioxa clinical results: Kmax stayed improved by 1.9 diopters at three years after one treatment, with no serious adverse events. What it means.
DCC Backs Red Warning on Cough Syrups for Children Under 4
Indian drug panel recommends a red warning on cough syrup labels for children under 4 and a ban on child imagery. What changes, the legal steps and advice.
Physical AI in Healthcare: 7 Trends Reshaping Care in 2026
Physical AI in healthcare is the fastest-growing application at 18% of a USD 5.0B market in 2025. Seven trends, data and risks, per Acumen Research.
Happy Ring Gets FDA Clearance for Cuffless Blood Pressure
Happy Health says its ring won FDA clearance for cuffless, calibration-free blood pressure measurement. What is confirmed, what is not and why it matters.
Kenya Confirms First Ebola Case and Death as Congo Spreads
Kenya confirms its first Ebola case and death in a traveller from Congo. What is known, contact tracing, outbreak figures and how to stay safe.
BD Commits $19 Billion to US Medical Supply Manufacturing
BD plans a $19 billion US investment to reach roughly 80% domestic supply of medical consumables, with tariff relief attached. Numbers and open questions.
Lupin Launches Formoflo-G Triple-Combination COPD Inhaler
Lupin launches Formoflo-G, a fixed-dose triple-combination MDI for COPD in India. What it contains, who it is for, what is unknown and the market context.
Infigratinib Gets FDA Priority Review for Achondroplasia
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.
EPCORE DLBCL-2: Epcoritamab Plus R-CHOP Cuts Risk 51%
Epcoritamab plus R-CHOP met the primary PFS endpoint in the Phase 3 EPCORE DLBCL-2 trial, cutting progression risk 51%. What it means for DLBCL.
Lilly Expands Gate Bioscience Deal to Over $870 Million
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.